Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The intravenous (IV) route for ibuprofen administration has a faster onset of action as compared to the other routes. IV ibuprofen is preferred for the management of post-operative and acute pain. The demand for ibuprofen has increased due to the side effects of opioid analgesics such as respiratory depression, allergic reactions, sedation, and gastrointestinal events.
The market for IV ibuprofen for pain management is in its nascent stage. The world IV ibuprofen market was valued at $3.6 million in 2015, and is projected to reach $14.2 million by 2022, registering a CAGR of 20% during the forecast period. Advantages associated with IV ibuprofen such as rapid result and targeted drug delivery have resulted in the growth of this market. In 2015, FDA approved IV ibuprofen for pediatric use, due to which the market is expected to register a significant growth during the forecast period. Other factors that affect the market growth significantly include increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, trauma, and shifting trend towards the use of non-opioids drugs. Factors that would hamper the market growth include side effects associated with IV ibuprofen and lengthy approval process.
The world IV Ibuprofen market is segmented on the basis of indication, age group, and country. By indication, further sub-segments considered in this report include pain/inflammation and fever. The age groups considered are pediatrics and adults. The market is segmented into four countries namely Australia, Canada, South Korea, and the U.S.
Currently, Cumberland Pharmaceuticals Inc., is the only IV ibuprofen manufacturer in the market. The company has collaborated with the local/regional drug manufacturers to target new countries by getting product approvals. The key companies profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc. (acquired by Teligent, Inc.), CSL Limited, Sandor Medicaids Pvt Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., and Laboratorios Valmorca, C.A.
KEY BENEFITS FOR STAKEHOLDERS:
INTRAVENOUS (IV) IBUPROFEN MARKET KEY SEGMENTS:
By Age Group
SIMILAR MARKET STUDIES
Glucose Meter is a medical device for determining the approximate concentration of glucose in the blood. It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart. It is a key element of home blood glucose monitoring (HBGM) by people with diabetes ...
September 2017 | $4880 | View Details >>
This report studies the Pet Insurance market, Pet insurance is a type of specialty property and casualty insurance policy that pet owners purchase to cover the unintended costs that arise in providing care for a pet, including veterinary services such as surgical procedures, injuries from accidents, and prescribed pet medicines. ...
September 2017 | $4880 | View Details >>
Geographically, this report is segmented into several key Regions, with production, consumption, revenue, market share and growth rate of Biofeedback Instrument in these regions, from 2012 to 2022 (forecast), covering North America Europe China Asia (Ex. China) RoW The major players in global Biofeedback Instrument market include Thought Technology Ltd Laborie Qxsubspace Vishee Quantum World Vision BrainMaster Technologies, Inc. Mind Media NeuroCare Allengers Medical Systems ELMIKO NCC ...
September 2017 | $2900 | View Details >>
This report studies the Irreversible Electroporation Ablators market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Irreversible Electroporation Ablators market by product type and applications/end industries. The ...
September 2017 | $4000 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research